ReachMD

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Vizitează neapărat site-ul podcastului și susține-i creatorul: reachmd.com

Autor

ReachMD

Categorie

Science

Site-ul podcastului

reachmd.com

Cel mai nou episod

20 oct. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/a-case-of-missed-diagnosis-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37713/ In this case-based presentation, Dr. Esther Lee Kim reviews a young patient with long-standing type 2 diabetes who presented with bilateral vision loss and was initially referr...

Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/patient-at-high-risk-of-loss-to-follow-up-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37711/ In this clinical discussion, Dr. Deepak Sambhara presents a case of a working-age man with severe non-proliferative diabetic retinopathy and diabetic macular ede...

Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-cultural-and-communication-disconnects-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37710/ In this case-based discussion, Dr. David Chin Yee presents his challenges and outcomes when managing a patient with diabetic macular edema who initially...

RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early effi...

Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition...

Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inh...

NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review ea...

Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, revi...

Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review...

Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, revi...

RAS Across Tumors: Who to Test When 29.01.2026

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from ag...

From Pixels to Practice: Advancing HCM Care With Multimodality Imaging 28.01.2026

CME credits: 0.75 Valid until: 28-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/ This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imagin...

Frontline Insights: Emerging Therapeutic Strategies in HNSCC 27.01.2026

CME credits: 0.25 Valid until: 27-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/Frontline-Insights-Emerging-Therapeutic-Strategies-in-HNSCC/49223/ This online educational activity highlights cutting-edge clinical trial data shaping the future of care in both locally advanced and recurrent/metastatic HNSCC. Experts review novel approaches such as perioperative immunotherapy, rad...

Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma 23.01.2026

CME credits: 0.25 Valid until: 23-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-line-moving-bispecific-antibodies-upstream-in-treating-multiple-myeloma/49265/ This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that su...

No Patient with CKD Left Behind! Emerging CKD Therapies in T1D 16.01.2026

CME credits: 0.50 Valid until: 16-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-emerging-ckd-therapies-in-t1d/36524/ Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in...

Interdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care 15.01.2026

CME credits: 1.00 Valid until: 15-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/interdisciplinary-strategies-for-brca-mutated-ebc-testing-targeting-and-team-based-care/36606/ This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the manag...

Oh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management 06.01.2026

CME credits: 1.00 Valid until: 06-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/oh-the-hats-youll-wear-the-many-modalities-of-pediatric-obesity-management/39966/ On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes. =

Addressing Unmet Needs in Metastatic Uveal Melanoma 05.01.2026

CME credits: 1.00 Valid until: 05-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/ Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the trea...

Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence 05.01.2026

CME credits: 1.00 Valid until: 05-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/spotlight-on-systemic-sclerosis-pathophysiology-presentation-emerging-evidence/48716/ Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for I...

Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL 02.01.2026

CME credits: 1.00 Valid until: 02-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/asparaginase-based-treatment-young-adults-all/37193/ Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult p...

Case Review: Targets Are Met—Can You Stick the Landing? 31.12.2025

CME credits: 1.00 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing...

Switching Strategies: Switch or Stay—What’s Your Call? 31.12.2025

CME credits: 1.00 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing di...

Remission: Can You Prove It? 31.12.2025

CME credits: 1.00 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/remission-can-you-prove-it/51486/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then exp...

Treat-to-Target: Are We There Yet? 31.12.2025

CME credits: 1.00 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, th...

Case Review: Can You Crack This IBD Case? 31.12.2025

CME credits: 1.00 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease sever...

Ascultă podcastul ReachMD CME în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice